KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.
You may also be interested in...
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
KemPharm And The Curious Case Of Launching A Brand Opioid Like A Generic
KemPharm is looking to sign a generic drug partner to launch its new brand opioid Apadaz, which says a lot about how the commercial promise of abuse-deterrent opioids has so far failed to materialize.
Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews
The latest drug development news and highlights from our US FDA Performance Tracker.